You are here: Home » PTI Stories » National » News
Business Standard

USFDA conducts inspection at Cipla's Indore facility

Press Trust of India  |  New Delhi 

Drug today said the US health regulator has conducted an at its facility and has not issued any or repeat observations.

"The Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) at its formulations facility from April 2, 2018 till April 13, 2018," said in a BSE filing.

There were no and/or repeat observations, it added.

The company, however, did not provide the details of observations it has received.

"At this stage, the company believes the observations are unlikely to have any material adverse impact. The Company will submit the response within the stipulated time frame," said.

Shares of today closed at Rs 583.55 per scrip on BSE, up 5.22 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, April 16 2018. 21:00 IST